Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMT-c Lactobacillus
- Development stage
- Unknown
- Lead developer
- Universidad Autónoma de Nuevo León
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
FMT-c Lactobacillus is an investigational microbiome-based therapy developed by researchers at the Universidad Autónoma de Nuevo León (UANL) for the treatment of recurrent Clostridioides difficile infection (rCDI). The formulation consists of fecal microbiota transplant (FMT) material derived from healthy donor stool, which is then enriched with three specific species of Lactobacillus. Delivered orally via capsules, the therapy is designed to restore intestinal microbial diversity and resolve dysbiosis more effectively than standard FMT by leveraging the synergistic effects of the donor's complex microbiota and the added probiotic strains. Clinical studies, including a randomized pilot trial (NCT03804736), have evaluated its efficacy in achieving clinical resolution of rCDI and restoring the gut microbiome's genomic profile.
- Other names
- Lactobacillus-enriched fecal microbiota transplantFecal microbiota transplant capsules enriched with lactobacilli
Beyond the preview
Go deeper on FMT-c Lactobacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMT-c Lactobacillus.